

REPORT ID AF-2026-412667	VERIFICATION CODE GP9X-WBGW	CLIENT China Peptide Source	STATUS ACTIVE
PRODUCT CJC-1295 no DAC 5 mg + Ipamorelin 5 mg Blend	BATCH / LOT CJIP-3719	SAMPLE RECEIVED Jul 28, 2026	ANALYSIS DATE Jul 30, 2026

CORE ANALYTICAL PANEL

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Purity	RP-HPLC	99.65%	≥99.00%	Conforms
Multi-Analyte Assay	HPLC (Component Profile)	All declared components resolved	Declared component profile	Conforms
Net Content Quantity	Gravimetric	10.015 mg	10 mg Target	Conforms

BIOSAFETY & SCREENING

SAFETY TEST	METHOD	OBSERVED LEVEL	LIMIT	STATUS
Endotoxin Assay (LAL)	LAL	0.620 EU/mg	≤ 5.0 EU/mg	Pass
Heavy Metal Screen (ICP-MS)	ICP-MS	0.029 ppm	< 0.1 ppm	Pass

ADDITIONAL ANALYTICAL RESULTS

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Component Ratio	HPLC (Component Area Ratio)	1:1 (CJC-1295 no DAC:Ipamorelin)	Declared ratio 1:1	Conforms
Appearance	Visual Inspection	White lyophilized cake	Product specification	Conforms
Water Content	Karl Fischer	0.40%	≤ 1.0%	Pass
Related Substances	RP-HPLC (Impurities)	< 0.10%	≤ 1.0%	Pass
Residual Solvents	Headspace GC	< 10 ppm	≤ 5000 ppm	Pass

METHOD & SAMPLE SUMMARY

PRIMARY METHOD RP-HPLC	MATRIX Lyophilized Blend	SAMPLE SIZE 10 mg
METHOD REFERENCE AF-MULTI-QC-01	OVERALL DISPOSITION CONFORMS	

VERIFICATION

GP9X-WBGW

<https://analyticalformulations.com/verify/GP9X-WBGW>

Lab ID: AFL-001 · FormuVerify™



Scan to verify certificate